2026-04-18T07:59:16Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1107692025-12-05T01:40:51Zcom_2072_1057col_2072_478917

Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway Chaccour, Carlos Rabinovich, Regina Malària Assaigs clínics Malaria Clinical trials The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested. 2017-05-10T13:26:31Z 2017-05-10T13:26:31Z 2017-04-24 2017-05-03T18:01:50Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1475-2875 https://hdl.handle.net/2445/110769 28434405 eng Reproducció del document publicat a: http://dx.doi.org/10.1186/s12936-017-1802-3 Malaria Journal, 2017, vol. 16, num. 1, p. 166 http://dx.doi.org/10.1186/s12936-017-1802-3 cc by (c) Chaccour et al., 2017 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess 13 p. application/pdf Biomed Central Articles publicats en revistes (ISGlobal)